Storia in 20 fonti

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor, received approval for patients who previously received at least one prior line of systemic therapy and are not candidates for multiagent systemic therapy.

Raccontata da

thestar.com+8 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo1 g fa

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

originale

Timeline cronologica

mercoledì 26 agosto 2026·forbes.com
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
mercoledì 26 agosto 2026·biopharmadive.com
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly…

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

Confronto fonti

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

Timeline cronologica

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

FDA approves landmark pancreatic cancer drug that's shown to improve survival

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

FDA approves breakthrough drug to treat advanced pancreatic cancer

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

FDA approves landmark pancreatic cancer drug that’s shown to improve survival

Estados Unidos aprobó un nuevo fármaco para el tratamiento del cáncer de páncreas avanzado

Tumore del pancreas, via libera negli Usa alla prima terapia mirata contro il gene killer RAS

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post

New hope for pancreatic cancer patients after FDA approves drug to improve survival

FDA approves ‘game-changing’ pancreatic cancer drug

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

Tumore al pancreas: nuovo trattamento in compresse raddoppia la sopravvivenza